Spero Therapeutics, Inc.
Spero Therapeutics is a clinical-stage biopharmaceutical company developing SP001, a third-generation Fc-silent anti-CD40L monoclonal antibody for IgG4-related disease and other immune-mediated conditions.
6-KSep 8Latest SEC filing, period to Sep 8
Aug 28Latest story